Li Linjun, Zhang Cheng, Luo Jun, Zhou Ruiqin, Zhou Guoqing, Wu Qingchen
Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Department of Traditional Chinese Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Front Med (Lausanne). 2025 Jun 25;12:1595640. doi: 10.3389/fmed.2025.1595640. eCollection 2025.
Brachytherapy based on iodine-125 (I-125) is becoming one of the alternative treatment option for advanced non-small cell lung cancer (NSCLC). Chinese herbal medicine (CHM) combined with radiotherapy reduces the complications. In the current study, we attempted to assess the outcomes of treating strategies using CHM, chemotherapy or I-125. 182 patients who underwent I-125 seed implantation alone or in combination with chemotherapy or CHM treatment were enrolled in the current study. The clinical information of the patients were collected, and analyzed after a 5-year follow-up. The overall survival rates at 1, 2, 3, and 5 years were 81, 47, 28, and 20%, respectively, with a median survival time of 24.28 months. For patients receiving chemotherapy combined with I-125 seed brachytherapy, the survival rates were 89, 53, 35, and 29%, respectively. In contrast, those treated with CHM combined with I-125 seed brachytherapy had survival rates of 90, 63, 42, and 23%. Meanwhile, the survival rates for patients treated with I seed brachytherapy alone were 69, 32, 12, and 11%. Additionally, patients receiving CHM combined with I-125 seed brachytherapy treatment also showed less complications such as cough and vomit. CHM treatment demonstrated comparable efficacy and less complications to chemotherapy in managing advanced NSCLC under the treatment of I-125.
基于碘-125（I-125）的近距离放射治疗正成为晚期非小细胞肺癌（NSCLC）的替代治疗选择之一。中药（CHM）联合放射治疗可减少并发症。在本研究中，我们试图评估使用CHM、化疗或I-125的治疗策略的结果。本研究纳入了182例单独接受I-125粒子植入或联合化疗或CHM治疗的患者。收集患者的临床信息，并在5年随访后进行分析。1年、2年、3年和5年的总生存率分别为81%、47%、28%和20%，中位生存时间为24.28个月。对于接受化疗联合I-125粒子近距离放射治疗的患者，生存率分别为89%、53%、35%和29%。相比之下，接受CHM联合I-125粒子近距离放射治疗的患者生存率为90%、63%、42%和23%。同时，单独接受I粒子近距离放射治疗的患者生存率为69%、32%、12%和11%。此外，接受CHM联合I-125粒子近距离放射治疗的患者咳嗽和呕吐等并发症也较少。在I-125治疗晚期NSCLC时，CHM治疗与化疗疗效相当，并发症更少。
